ReviewBiochimica et biophysica acta. Reviews on cancer2017
Changing mutational and adaptive landscapes and the genesis of cancer.
Review in Biochimica et biophysica acta. Reviews on cancer, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 48 citations in OpenAlex.
- Age-related decline in niche self-renewal factors drives testis aging via Hairless, Imp, and Chinmo.Science advances · 2026Article
- Single cell-spatial transcriptomics and bulk multi-omics analysis of heterogeneity and ecosystems in hepatocellular carcinoma.NPJ precision oncology · 2024Article
- Tenascin-C in the early lung cancer tumor microenvironment promotes progression through integrin αvβ1 and FAK.bioRxiv : the preprint server for biology · 2024Article
- Exploring the Role of Clustered Mutations in Carcinogenesis and Their Potential Clinical Implications in Cancer.International journal of molecular sciences · 2024Review
- Pairwise and higher-order epistatic effects among somatic cancer mutations across oncogenesis.Mathematical biosciences · 2023Article
- Elucidating the clonal relationship of esophageal second primary tumors in patients with laryngeal squamous cell carcinoma.Infectious agents and cancer · 2023Review
- Stem cell mutations, associated cancer risk, and consequences for regenerative medicine.Cell stem cell · 2023Review
- Intratumor microbiome: selective colonization in the tumor microenvironment and a vital regulator of tumor biology.MedComm · 2023Review
- Skin aging from the perspective of dermal fibroblasts: the interplay between the adaptation to the extracellular matrix microenvironment and cell autonomous processes.Journal of cell communication and signaling · 2023Review
- Inferring the Cancer Cellular Epigenome Heterogeneity via DNA Methylation Patterns.Cancer treatment and research · 2023Article
- Attribution of Cancer Origins to Endogenous, Exogenous, and Preventable Mutational Processes.Molecular biology and evolution · 2022Article
- Mutation signatures of pediatric acute myeloid leukemia and normal blood progenitors associated with differential patient outcomes.Blood cancer discovery · 2021Article
- Playing cancer at its own game: activating mitogenic signaling as a paradoxical intervention.Molecular oncology · 2021Review
- Relationship between Urban Green Spaces and Cancer: A Scoping Review.International journal of environmental research and public health · 2021Article
- Plasma Metabolome Signature Indicative ofFrontiers in oncology · 2021Article
- Baicalin, a Potent Inhibitor of NF-κB Signaling Pathway, Enhances Chemosensitivity of Breast Cancer Cells to Docetaxel and Inhibits Tumor Growth and Metastasis BothFrontiers in pharmacology · 2020Article
- Tumour Initiation: a Discussion on Evidence for a "Load-Trigger" Mechanism.Cell biochemistry and biophysics · 2019Review
- Somatic maintenance impacts the evolution of mutation rate.BMC evolutionary biology · 2019Article
- Review
- Time-restricted feeding delays the emergence of the age-associated, neoplastic-prone tissue landscape.Aging · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
By the time the process of oncogenesis has produced an advanced cancer, tumor cells have undergone extensive evolution. The cellular phenotypes resulting from this evolution have been well studied, and include accelerated growth rates, apoptosis resistance, immortality, invasiveness, and immune evasion. Yet with all of our current knowledge of tumor biology, the details of early oncogenesis have been difficult to observe and understand. Where different oncogenic mutations may work together to enhance the survival of a tumor cell, in isolation they are often pro-apoptotic, pro-differentiative or pro-senescent, and therefore often, somewhat paradoxically, disadvantageous to a cell. It is also becoming clear that somatic mutations, including those in known oncogenic drivers, are common in tissues starting at a young age. These observations raise the question: how do we largely avoid cancer for most of our lives? Here we propose that evolutionary forces can help explain this paradox. As humans and other organisms age or experience external insults such as radiation or smoking, the structure and function of tissues progressively degrade, resulting in altered stem cell niche microenvironments. As tissue integrity declines, it becomes less capable of supporting and maintaining resident stem cells. These stem cells then find themselves in a microenvironment to which they are poorly adapted, providing a competitive advantage to those cells that can restore their functionality and fitness through mutations or epigenetic changes. The resulting oncogenic clonal expansions then increase the odds of further cancer progression. Understanding how the causes of cancer, such as aging or smoking, affect tissue microenvironments to control the impact of mutations on somatic cell fitness can help reconcile the discrepancy between marked mutation accumulation starting early in life and the somatic evolution that leads to cancer at advanced ages or following carcinogenic insults. This article is part of a Special Issue entitled: Evolutionary principles - heterogeneity in cancer?, edited by Dr. Robert A. Gatenby.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.